BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Sapheon, Inc. Receives CE Mark Approval for New Varicose Vein Treatment


9/22/2011 6:36:48 AM

SANTA ROSA, Calif.--(BUSINESS WIRE)-- Sapheon Inc. announced that it has received CE Mark approval for its new approach to the treatment of varicose veins caused by venous reflux disease. The Sapheon Closure System addresses the estimated one million procedures performed each year to close the great saphenous vein. Sapheon’s technology uses an advanced proprietary medical adhesive and single-use catheter-based delivery system to immediately and permanently achieve vein closure without thermal ablation or sclerosing chemicals. Patients treated with the Sapheon Closure System avoid significant post procedure pain and bruising, do not need to wear compression stockings, and can immediately resume normal lifestyle activities.

Unlike current thermal ablation procedures, the Sapheon treatment does not require tumescent anesthesia or patient sedation.

“Treatment of incompetent great saphenous vein segments with the Sapheon technology is safe and effective,” according to Dr. Thomas Proebstle of Mannheim, Germany, a clinical investigator and early adopter of the Sapheon Closure System. “It is a welcome and exciting improvement over existing vein closure technologies.”

“We are pleased to receive the regulatory go-ahead to introduce our product to physicians and patients in the European Union and other countries outside the U.S.,” said Don Crawford, President and CEO of Sapheon. “We believe that the Sapheon approach is the future of vein disease treatment.”

Distribution of the Sapheon Closure System within the EU will commence in the fourth quarter of 2011. The Company plans to initiate a post-market study — the European Sapheon Closure System Observational ProspectivE (eSCOPE ) Trial — in the EU starting in November 2011.

Sapheon will be presenting the Sapheon Closure System at the FDA Tissue Adhesives Symposium to be held at the FDA White Oak Campus in Silver Spring, Maryland, September 26-27, 2011.

About Sapheon

Sapheon is an early stage medical device company whose mission is to develop new approaches for the treatment of vascular disease. Our current focus is on technology to improve the treatment of varicose veins caused by venous reflux disease. Please visit www.sapheoninc.com to learn more about our business.

Contact:

Sapheon Inc.Harry Phillips, 707-206-6820harry.phillips@sapheon.net


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->